Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice-Reference-Cited by-同舟云学术

Sodium‐glucose co‐transporter‐2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice

Published:2022-03-30 Issue:7 Volume:24 Page:1187-1196
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Khunti Kamlesh¹²^ORCID,Jabbour Serge³^ORCID,Cos Xavier⁴⁵,Mudaliar Sunder⁶⁷,Mende Christian⁸,Bonaca Marc⁹,Fioretto Paola¹⁰^ORCID

Affiliation:

1. Diabetes Research Centre, College of Medicine, Biological Sciences and Psychology University of Leicester Leicester UK

2. NIHR Applied Research Collaboration ‐ East Midlands Leicester UK

3. Thomas Jefferson University Philadelphia Pennsylvania USA

4. Sant Marti de Provençals Primary Care Centres Barcelona Spain

5. Institut Català de la Salut. IDIAP Jordi Gol. DAP_Cat Study Group CIBERDEM Universitat Autonoma de Barcelona Barcelona Spain

6. Department of Medicine University of California, San Diego School of Medicine San Diego California USA

7. Veterans Affairs Medical Center San Diego California USA

8. Department of Medicine University of California San Diego La Jolla California USA

9. Department of Medicine, Division of Cardiology University of Colorado School of Medicine, Aurora CO; CPC Clinical Research Aurora Colorado USA

10. Department of Medicine University of Padua, Unite of Medical Clinic 3, Hospital of Padua Padua Italy

Funder

AstraZeneca Pharma Poland

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14684

Reference92 articles.

1. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025

2. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition

3. American Diabetes Association professional practice committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical Care in Diabetes—2022;Diabetes Care,2021

4. Trends in diabetes medication use in Australia, Canada, England, and Scotland: a repeated cross-sectional analysis in primary care

5. A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022;British Journal of Clinical Pharmacology;2024-09-03

2. Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis;Atherosclerosis;2024-09

3. Early Identification and Management of Chronic Kidney Disease: A Narrative Review of the Crucial Role of Primary Care Practitioners;Advances in Therapy;2024-08-20

4. Bexagliflozin in type 2 diabetes: a profile of its use;Drugs & Therapy Perspectives;2024-07

5. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile;Expert Opinion on Drug Safety;2024-05-13